Ipilimumab

Sara Tolaney, MD, MPH, spoke with Healio about results from the NIMBUS trial presented at San Antonio Breast Cancer Symposium 2021.

Nivolumab plus ipilimumab induced durable responses among a small cohort of women with high tumor mutational burden metastatic HER2-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer than those who received the reverse sequence, according to study findings.

First-line nivolumab plus ipilimumab conferred greater long-term clinical benefit than sunitinib for patients with advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

The FDA granted fast track designation to UV1 in combination with checkpoint inhibitor therapy for treatment of unresectable or metastatic melanoma.

The combination of nivolumab and ipilimumab maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results.

First-line nivolumab plus ipilimumab conferred durable survival benefit compared with sunitinib for patients with advanced renal cell carcinoma, according to results of the randomized phase 3 CheckMate-214 trial.

Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer.

The addition of nivolumab and ipilimumab to first-line chemotherapy conferred durable survival benefits to patients with advanced non-small cell lung cancer and brain metastases, according to results of the phase 3 CheckMate 9LA trial.

A phase 3 trial of nivolumab plus ipilimumab vs. the EXTREME regimen as first-line treatment of advanced squamous cell carcinoma of the head and neck failed to meet its primary endpoints of OS, according to a company-issued press release.